false
0001476963
0001476963
2024-08-06
2024-08-06
0001476963
us-gaap:CommonStockMember
2024-08-06
2024-08-06
0001476963
SCPX:CommonStockPurchaseRightsMember
2024-08-06
2024-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(date of earliest event reported): August 6, 2024
Scorpius Holdings, Inc.
(Exact name of registrant
as specified in charter)
Delaware
(State or other jurisdiction
of incorporation)
| 001-35994 |
26-2844103 |
| (Commission File Number) |
(IRS Employer Identification
No.) |
627 Davis Drive, Suite 300
Morrisville, North Carolina 27560
(Address of principal
executive offices and zip code)
(919)
240-7133
(Registrant’s
telephone number including area code)
(Former Name and Former
Address)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following
provisions:
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, $0.0002 par value per share |
SCPX |
NYSE American LLC |
| Common Stock Purchase Rights |
None |
NYSE American LLC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company ¨ |
|
If an emerging growth
company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01
Entry into a Material Definitive Agreement.
On
August 6, 2024, Scorpius Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”)
with ThinkEquity LLC (the “ThinkEquity”), as representative of the several underwriters named therein (the “Underwriters”),
pursuant to which the Company agreed to issue and sell to the several Underwriters in a firm commitment public offering (the “Offering”)
12,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.002 per share (the “Common Stock”),
or pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”)
in lieu thereof, at a purchase price of $0.93 per Share and $0.929814 per Pre-Funded Warrant (93% of the public offering price per Share
or Pre-Funded Warrant).
On
August 7, 2024, ThinkEquity provided the Company with a notice of termination of the Underwriting Agreement based on the suspension of
the trading in the Company’s Common Stock on the NYSE American, LLC (“NYSE American”), and as result of the unexpected
decision by the staff of the NYSE American with respect to its treatment of the announced public Offering by the Company.
The Shares, the Pre-Funded Warrants and the Pre-Funded
Warrant Shares (collectively referred to as the “Securities”) are being offered by the Company pursuant to the Company’s
Registration Statement on Form S-1 (File No. 333-280887), as amended to date, filed by the Company with the Securities and Exchange Commission
(the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), that became effective on August
6, 2024. A new underwriting agreement will be entered into if a subsequent offering is consummated and the closing of the Offering is
expected to occur on or about August 19, 2024. Trading of the Company’s Common Stock was halted by NYSE American as of August 7,
2024.
The
foregoing does not purport to be a complete description of the Underwriting Agreement and is qualified in its entirety by reference to
the full text of such document, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
1.02 Termination of Material Definitive Agreement
The
information contained in Item 1.01 is incorporated herein by reference.
Item 7.01
Regulation FD Disclosure.
On August 9, 2024, the Company issued a press release
announcing that Company has requested, and the NYSE American has approved, a financial viability exception to the NYSE American stockholder
approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to pursue the sale
of 12,500,000 shares of common stock (or Pre-Funded Warrants in lieu thereof), exclusive of the over-allotment option, at a price of $1.00
per share (inclusive of the Pre-Funded Warrant exercise price). The Underwriting Agreement was terminated in connection with the Offering
and a new underwriting agreement will be entered into if the offering is consummated. There can be no assurance that the Company will
be able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the
exemption, as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing
of a notification letter to the Company’s stockholders.
The Audit Committee of the Company’s
Board of Directors (the “Board”), composed solely of independent and disinterested members of the Board, determined that the
delay associated with obtaining a stockholder vote prior to consummation of the Offering and the issuance of the Securities would seriously
jeopardize the financial viability of the Company, and, on that basis, the Audit Committee expressly approved the Company’s reliance
on the financial viability exception to the requirement to seek stockholder approval. A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
In accordance with NYSE American requirements,
the Company will mail a letter to stockholders, not later than ten days prior to the anticipated closing of the issuance of the Securities,
notifying them of its agreement with ThinkEquity, pursuant to an underwriting agreement, to, among other things, issue the Securities
upon consummation of the Offering, without obtaining approval from its stockholders (the “Stockholder Letter”). A copy of
the Stockholder Letter to be mailed is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into
this Item 7.01.
The information under this Item 7.01, including
Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
(the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by
reference into the filings of the Company under the Securities Act or the Exchange Act.
Item
8.01. Other Events
On August 9, 2024, the Company issued a press release
announcing that Company has requested, and the NYSE American has approved, a financial viability exception to the NYSE American stockholder
approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to pursue the sale
of 12,500,000 shares of common stock (or Pre-Funded Warrants in lieu thereof), exclusive of the over-allotment option, at a price of $1.00
per share (inclusive of the Pre-Funded Warrant exercise price). The Underwriting Agreement was terminated in connection with the Offering
and a new underwriting agreement will be entered into if the offering is consummated. There can be no assurance that the Company will
be able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the
exemption, as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing
of a notification letter to the Company’s stockholders.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: August 9, 2024 |
SCORPIUS HOLDINGS, INC. |
| |
|
| |
|
|
| |
By: |
/s/ Jeffrey
Wolf |
| |
Name: |
Jeffrey Wolf |
| |
Title: |
Chairman, President and
Chief Executive Officer |
Exhibit 99.1
Scorpius Holdings,
Inc. Provides Update on Its
Previously Announced Public Offering
DURHAM, N.C. – August 9, 2024 —
Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development
and manufacturing organization (CDMO), today announced a delay in its previously announced public offering. The Company has requested,
and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that would allow it to proceed
with the closing of an underwritten public offering. The Company intends to pursue the sale of 12,500,000 shares of common stock (or pre-funded
warrants (“Pre-Funded Warrants”) in lieu thereof, exclusive of the over-allotment option) at a price of $1.00 per share (inclusive
of the Pre-Funded Warrant exercise price). The underwriting agreement was terminated in connection with the previously announced offering
and a new underwriting agreement will be entered into if the offering is consummated. There can be no assurance that the Company will
be able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the
exemption, as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing
of a notification letter to the Company’s shareholders.
The Company intends to use the net proceeds of the
offering to fund working capital and for general corporate purposes.
ThinkEquity is acting as sole book-running manager
for the offering.
A
registration statement on Form S-1 (File No. 333-280887), as amended, including a preliminary prospectus, relating to the securities being
offered was filed with the Securities and Exchange Commission (“SEC”) and became effective on August 6, 2024. This offering
is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State
Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the
SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.
About Scorpius Holdings,
Inc.
Scorpius
Holdings Inc. is an integrated large molecule contract development and manufacturing organization (CDMO) focused on rapidly advancing
biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development,
and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced
team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.
For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates," "intends,"
"plans," "believes," "estimates," and similar expressions and include statements regarding the repricing
of the offering, the ability to consummate an offering under the specified terms or otherwise the timing and completion of the proposed
offering and the intended use of proceeds. Important factors that could cause actual results to differ materially from current expectations
include, among others, the ability to complete the proposed offering, and other factors described in the Company’s annual report
on Form 10-K for the year ended December 31, 2023, subsequent quarterly report on Form 10-Q and any other filings the Company makes with
the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update
any forward-looking statements contained in this press release on account of new information, future events, or otherwise, except as required
by law.
For Investor Relations Inquiries:
David Waldman
+1 (919)-289-4017
investorrelations@nighthawkbio.com
Exhibit 99.2
August 8, 2024
Dear Shareholder,
I
am pleased to announce that, to strengthen its balance sheet, Scorpius Holdings, Inc. (the “Company,” “Scorpius,”
“we,” “our,” or “us”) has indicated its intent to consummate an underwritten
public offering and raise approximately $12,500,000 by selling 12,500,000 shares of common stock at a price of $1.00 per share (or pre-funded
warrants in lieu thereof). The securities will be registered on the Company’s registration statement on Form S-1 (File No. 333-280887).
In order to complete the financing and issue the common stock and pre-funded warrants, the Company has requested and received confirmation
from the NYSE American, LLC (“NYSE American”) that the NYSE American will not object to the Company’s reliance
on the financial viability exception to the NYSE American’s shareholder approval policy described in more detail below.
Background
As
previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2024 on a preliminary
unaudited basis, for the quarter ended June 30, 2024, the Company expects to recognize between $0.3 million and $0.8 million of revenue.
On a preliminary unaudited basis as of June 30, 2024, the Company expects its operating loss to be between $8.6 million and $9.1 million,
and net loss before income taxes from continuing operations to be between $9.2 million and $9.7 million. At June 30, 2024, the Company’s
cash and cash equivalents and short term investments was approximately $1.5 million, and the Company will need to raise additional capital
to fund its operations.
Revenue
generated for the six months ended June 30, 2024, has been primarily derived from process development work and does not include revenue
we anticipate generating from microbial cGMP manufacturing which we commenced in July 2024 or mammalian cGMP manufacturing which we anticipate
commencing in the third quarter of 2024. The Company anticipates that cGMP manufacturing contracts will generally be larger than
the process development contracts we have booked to date.
The
estimates of revenue, operating loss, and net loss before income taxes from continuing operations are the Company’s preliminary
estimates based on currently available information and are subject to completion of the Company’s financial closing procedures.
They do not present all necessary information for an understanding of the Company’s financial condition as of June 30, 2024 or its
results of operations for the three months ended June 30, 2024. The Company’s independent registered public accounting firm has
not conducted an audit or review of and does not express an opinion or any other form of assurance with respect to, the preliminary unaudited
revenue results. It is possible that the Company or its independent registered public accounting firm may identify items that require
the Company to make adjustments to the preliminary estimates of revenue, operating loss, and net loss before income taxes from continuing
operations set forth above. Accordingly, undue reliance should not be placed on the preliminary estimates.
Description of Financing
On
August 6, 2024, the Company announced the pricing of an underwritten public offering of 12,500,000
shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) at a public offering price of
$1.00 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds to the Company of approximately $12,500,000, before
deducting underwriting discounts and offering expenses. In addition, the Company announced that it intended to grant the underwriters
a 45-day option to purchase up to an additional 1,875,000 shares of common stock and/or Pre-Funded Warrants solely to cover over-allotments,
if any. A registration statement on Form S-1 (File No. 333-280887), as amended, including a preliminary prospectus, relating to the securities
being offered was filed with the Securities and Exchange Commission (the "Commission") and became effective on August
6, 2024. The underwriting agreement was terminated in connection with the previously announced offering and a new underwriting agreement
will be entered into if the offering is consummated.
The
Company has requested, and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that
would allow it to proceed with the closing of an underwritten public offering. The Company intends to pursue the sale of 12,500,000 shares
of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof, exclusive of the over-allotment option)
at a price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). There can be no assurance that the Company will be
able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the exemption,
as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing of a
notification letter to the Company’s shareholders. The offering is expected to close on or about August 21, 2024.
Notice of New
York Stock Exchange Exception
Section
710 of the NYSE American Company Guide would normally require shareholder approval prior to the consummation of the financing. However,
we requested and received confirmation from the NYSE American that the NYSE American will not object to the Company’s reliance on
the financial viability exception to the NYSE American’s shareholder approval policy pursuant to Section 710 of the NYSE American
Company Guide. The financial viability exception allows an issuer to issue securities upon application to the NYSE American when (1) the
delay in securing shareholder approval would seriously jeopardize the financial viability of the enterprise and (2) reliance by the
company on this exception is expressly approved by the audit committee of the company’s board of directors.
As
described above, prior to today’s announcement, the Audit Committee of the Company’s Board of Directors determined that the
delay associated with obtaining a shareholder vote prior to the consummation of the financing would seriously jeopardize the financial
viability of the Company and, on that basis, expressly approved reliance on the financial viability exception in order to consummate the
financing and related transactions without delay.
On August
8, 2024, the NYSE American confirmed that it will not object to the Company’s reliance on the financial viability exception, provided
that the Company complies with the conditions of the exception provided for in Section 710 of the NYSE American Company Guide. The
Company is mailing this letter to all shareholders not later than 10 days prior to the anticipated closing of the financing to alert investors
that the Company will not seek, and will not be required to seek, the shareholder approval that would otherwise be required under applicable
NYSE American rules. In addition to this notification, the Company has issued a press release publicly announcing the financing and
is filing a Current Report on Form 8-K with the Commission. For copies of the definitive agreements relating to the financing,
as well as information on related developments, please review our current and future reports on file with the Commission and available
at www.sec.gov.
Forward-Looking
Statements
Some
of the statements contained in this letter to shareholders are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future performance and include statements
about the adequacy, timing and structure of the proposed financing, whether the transactions contemplated thereunder will be completed,
the Company’s financial viability, as well as other statements that can be identified by the use of the forward-looking terminology
such as “agree,” “commit,” “may,” “will,” “anticipate,” “would,”
or similar terms, variations of such terms, or the negative of such terms. These forward-looking statements are based on the Company’s
current expectations and inherently involve significant risks and uncertainties.
Further
description of risks that could cause actual events to differ from the outcomes predicted by the Company’s forward-looking statements
is set forth under the caption “Risk Factors” in the Company’s annual report on Form 10-K and will be set
forth under the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q with the Commission,
and you should consider each of those factors when evaluating the forward-looking statements. These forward-looking statements speak only
as of the date of this letter and the Company undertakes no duty or obligation to update any forward-looking statements contained in this
letter as a result of new information, future events or changes in its expectations.
Thank
you for your continued support of Scorpius.
v3.24.2.u1
Cover
|
Aug. 06, 2024 |
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Aug. 06, 2024
|
| Entity File Number |
001-35994
|
| Entity Registrant Name |
Scorpius Holdings, Inc.
|
| Entity Central Index Key |
0001476963
|
| Entity Tax Identification Number |
26-2844103
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
627 Davis Drive
|
| Entity Address, Address Line Two |
Suite 300
|
| Entity Address, City or Town |
Morrisville
|
| Entity Address, State or Province |
NC
|
| Entity Address, Postal Zip Code |
27560
|
| City Area Code |
919
|
| Local Phone Number |
240-7133
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Entity Emerging Growth Company |
false
|
| Common Stock [Member] |
|
| Common Stock |
Common Stock, $0.0002 par value per share
|
| Trading Symbol |
SCPX
|
| Security Exchange Name |
NYSEAMER
|
| Common Stock Purchase Rights [Member] |
|
| Common Stock |
Common Stock Purchase Rights
|
| Trading Symbol |
None
|
| Security Exchange Name |
NYSEAMER
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=SCPX_CommonStockPurchaseRightsMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
Scorpius (AMEX:SCPX)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Scorpius (AMEX:SCPX)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024
